Biomet, a manufacturer of musculoskeletal medical devices, has acquired substantially all of the assets of Massachusetts-located Cytosol Laboratories, a provider of small volume anticoagulant products.

Cytosol develops anticoagulants and other products to aid in the processing of blood components. The company has three proprietary products with new drug application approvals: TriCitrasol, noClot-50 and Rejuvesol.

TriCitrasol is used for anticoagulation during granulocytapheresis while Rejuvesol is used for the rejuvenation of stored, frozen red blood cells prior to transfusion.

Stuart Kleopfer, president of Biomet Biologics, said: “This acquisition solidifies a critical supply component utilised by market-leading GPS III Platelet Separation System and BioCue Platelet Concentration System for concentrating a mixture of blood and bone marrow.

“In addition, given the increased scrutiny of stored red blood cells and increasing attention being paid by clinicians to the benefits of granulocytapheresis, both of these products have excellent market potential. We welcome the Cytosol team and are eager to explore additional indications for this unique product line.”

Headquartered in Warsaw, Indiana, Biomet and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy.

Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants.